Omarigliptin: A new kind of long acting DPP-4 inhibitor / 药物评价研究
Drug Evaluation Research
; (6): 133-137, 2017.
Artículo
en Chino
| WPRIM (Pacífico Occidental)
| ID: wpr-514995
Biblioteca responsable:
WPRO
ABSTRACT
Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day,which brings inconvenience to patients.Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor.The drug is developed by the Merck Co,mainly for the treatment of type two diabetes.The drug only need to be taken once a week,so as to improve the patient's compliance and adherence,thereby improving the therapeutic effect.This article introduces the information of omarigliptin from the aspects of synthesis,pharmacology,pharmacokinetics,and clinical research,which provides valuable information for pharmaceutical workers.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Drug Evaluation Research
Año:
2017
Tipo del documento:
Artículo